About MedAppropriate
Meet our Team
Perry Cohen
Chief Executive OfficerPharmacist by training
Cofounder and CEO of The Pharmacy Group, now with 5 business lines
COO of Aetna Pharmacy Management and helped create PBM industry in ‘90’s
Cofounder the Academy of Managed Care Pharmacy
Longstanding relationships with hundreds of decision makers in U.S. healthcare system
Deb d'Aquin
Chief Marketing OfficerConsumer & Technology Services Marketing
Codeveloped & sold 2 startups
Executive roles innovating and implementing new models for growth in and out of healthcare
Data-driven communication strategy and engagement
Marj Zimmerman
Chief Operating OfficerPharmacist by training
Pharmacist field operations and education innovator
Pioneered in-home chemotherapy model
Built decentralized pharmacy services model for large hospital pharmacy dept
Led industry efforts to measure impact of virtual and in-person intervention on physician prescribing behavior
Rich Balest
Chief Analytics OfficerPharmacist by training
Actuarial data modeling for leading Health Plans, PBM’s, and Academic Medical Centers
Deep analytical skills creating information and insights across pharmacy and medical claims data
Recognized expert at measuring prescription drug trends, PBM contracts and financial performance of employer sponsored prescription drug benefit plans
Medicare Part D and specialty network assessments, clinical pathways and case rate development
We’re supported by industry leading advisors
Gary S. Firestein, MD
Renowned Rheumatology Disease Specialist and Researcher
Current Dean and Associate Vice Chancellor of Translational Medicine, UC San Diego
Harvard College, Johns Hopkins University School of Medicine, Fellowships at Burnham Institute and UC San Diego.
Former Chair, FDA Arthritis Advisory Committee
Paul Fronstin, Ph. D.
Director, Health Research and Education, Employee Benefit Research Institute
Oversees Center for Research on Health Benefits Innovation
Expert Economic Research/Trends Employee Health Benefits
Washington DC. Government Health Policy
Lynn Franzoi
Widely Respected Fortune 500 Health Benefits Advisor
Former Head of Benefits across all of Fox Entertainment. Benefits Leadership Roles at Teledyne, American Honda, Pacific Life
Board of Directors, Delta Dental
Board Member, US Chamber of Commerce -Benefits Issues and Policy.
Testifies before Congress
Academy of Managed Care Pharmacy
David Feffer
Successful , serial consumer-centric Healthcare Services Entrepreneur
Expert in the finance, planning, and delivery of health care services
Co-founded Health Incentives, first telephonic nurse decision support company
Founded and headed Informed Health for Aetna
Joined, Built and Sold Health Dialog
Senior Consultant, Time Life Health and Array Health
Dr. Fred Wasserman
Built MaxiCare from a $27,000 capitalization into a $1.9 billion dollar company operating in 23 of the largest 30 US markets
Widely credited with creating the healthcare delivery model now known as the “Accountable Care Organization”
First introduced Nurse Practitioners, Health Educators and Quality Assurance programs into private practice settings
Member of the Board of Directors of the
La Jolla Institute for Allergy and Immunology.
Extensively published author
About MedAppropriate
MedAppropriate is at the nexus of reducing TOTAL COST OF CARE for chronically ill patients on specialty pharmaceuticals and improving outcomes.
We bend the specialty pharmaceutical cost curve by changing patient and physician behavior through HIGH-TECH DATA ANALYTICS and HIGH-TOUCH INTERVENTIONS.
We independently identify the right patient, populations and therapies, then execute appropriate interventions.
We're not alone in tackling the high cost of specialty pharmaceuticals, but we are alone in our independence from the vested interests of other stakeholders. We also get right to the root of the problem, sub-optimal prescribing and patient behavior.
More than 140 years of combined managed care, pharmacy benefit management, consumer and data analytics specialization has enabled us to build MedAppropriate around two key insights.
- Identifying the highest-cost and risk patients requires analyzing both medical and pharmacy claims data in an unbiased way. This also lets us pinpoint the patients most likely to positively respond to intervention.
- Face-to-face interventions with patients and physicians by carefully trained pharmacist drug therapy advisors has an outsized impact on changing prescribing and patient utilization behavior.